Developing accurate predictive models for patients with pediatric acute myeloid leukemia (AML) can close the preclinical gap in treatment for the rare disease. Unlike adult patients who have patients, ...

Recently recognized by the World Health Organization, acute myeloid leukemia (AML) with t(7;12)(q36;p13) has previously been associated with MNX1 and ETV6 signaling, although MNX1::ETV6 fusion ...

(RTTNews) - SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company, Tuesday announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric ...

Despite improved outcomes in newly diagnosed pediatric AML, relapsed disease remains a therapeutic challenge. Factors contributing to slow progress in improving outcomes include inherent challenges in ...

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia ...

SELLAS Life Sciences Group, Inc. announced that it has dosed its first pediatric patient in a Phase 2 trial for SLS009 (tambiciclib), a selective CDK9 inhibitor targeting relapsed/refractory acute ...

Removing etoposide did not negatively affect OS, DFS, MRD, or relapse rate at 3 years for low- and high-risk patients. Removing etoposide from frontline induction chemotherapy did not appear to ...

It seemed as if Logan Jenner had the best possible chance for a cure. Diagnosed at age 3 with acute myeloid leukemia, an aggressive blood cancer, Logan happened to have a targetable mutation that ...

Soheil Meshinchi, MD, PhD, a world leader in developing novel approaches to treating acute myeloid leukemia (AML), has been ...

Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid leukemia (AML) have made enormous progress during the past decades. Because AML is a rare type of childhood cancer, ...